To determine the effect of topical insulin of 3 concentrations [0.5, 1, and 2 units per drop 4 times per day (QID)] on postoperative corneal epithelial wound healing in diabetic patients.
D
iabetic keratopathy is increasingly recognized as an important cause of ocular morbidity that potentially leads to blindness apart from diabetic retinopathy.
1-4 Morphology of corneal epithelium is altered in diabetic keratopathy and leads to epithelium fragility. This alteration causes abnormal basement membrane structure and poor epithelial adherence, which affects the rate of epithelial healing and compromises epithelial barrier function.
Other corneal changes resulting from diabetes include neuropathy and alterations in the corneal stroma, Descemet membrane, and corneal endothelium. The cornea of individuals with diabetes could seem normal until the corneal surface is damaged and epithelial healing is delayed. Sequelae can range from infectious corneal ulcers to secondary corneal scarring and finally permanent loss of vision.
3,4 Thus, rapid resurfacing of injured corneal epithelium is needed to reestablish corneal function.
Diabetic keratopathy presents as a nonhealing epithelial defect that is usually difficult to treat with conventional measures. Topical lubricants and prophylactic antibiotics are the usual choice for such cases, especially in postoperative patients. Despite these measures, the epithelium may take a long time to recover, hence predisposing patients to infective keratitis, particularly when the patient is immunocompromised or has poor diabetic control.
Corneal epithelial defect can be due to nonsurgical or surgical trauma, 3,4 such as vitrectomy or cataract surgery. Occasionally during surgery, corneal epithelial debridement becomes necessary to improve surgeons' visibility, especially during complex vitrectomy cases with long duration of surgery where the cornea becomes edematous. The frequency of corneal debridement during diabetic vitrectomy has been reported to range from 0-90%, with an average range of 17.4%. 5 Chen et al 6 in 2016 investigated the incidence of persistent corneal epithelial defect after vitrectomy and the rate was 4.6% (21/460 eyes). Therefore, the healing of these iatrogenic wounds within the shortest possible time becomes paramount. 7 Insulin is a peptide closely related to insulin-like growth factor (IGF) that is able to stimulate haptotactic migration of human epidermal keratinocytes and is implicated in wound repair.
8 Insulin is present in human tear film and insulin receptors have also been detected in the human ocular surface and cornea.
9 However, its function is still unknown.
An animal study by Zagon et al 10 found that topical insulin had no effect on corneal re-epithelialization of nondiabetic rats. However, diabetic rats treated with topical insulin 1 unit 4 times daily had significantly enhanced corneal healing relative to diabetic rats without topical insulin. 10 The study also found that topical insulin had no effect on blood glucose levels or on ocular pressure as measured before or 2 weeks after debridement. This study was the first to demonstrate that topical application of insulin enhances corneal wound healing in a diabetes animal model. Bartlett et al 11, 12 found that topical insulin eye drops up to 100 units/mL twice daily had no ocular side effect on human study in normal individuals. There was no systemic absorption of insulin based on blood glucose levels and serum immune-reactive insulin levels. Insulin eye drops in this study were subjectively as comfortable and objectively as clinically innocuous as sterile saline.
In the retrospective study by Bastion et al, 7 topical insulin (Actrapid; Novo Nordisk) 1 unit 4 times daily was used for ocular therapy and showed improvement in the healing rate of diabetic patients with corneal epithelial defect after vitrectomy compared with the control group with no adverse events reported. Apart from this study, there are no published series on the usage of topical insulin for epithelial defects after ocular surgery.
Topical usage of a widely used drug that is accepted for systemic usage, relatively cheap, and readily available for a group of patients that is growing in number (diabetic patients) has widespread implications for our local population. Thus, this study was conducted to investigate various concentrations of topical insulin for healing of corneal epithelial defect after corneal debridement during intraocular surgery compared with diabetic placebo.
MATERIALS AND METHODS
Patients who underwent vitrectomy with postoperative corneal epithelial defect and fulfilled the inclusion and exclusion criteria from December 2014 to October 2016 were recruited. The study was conducted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC), a tertiary referral center and teaching hospital in the capital of Malaysia. The study was approved by the UKM research ethics committee (trial number: UKM 1.5.3.5/244/GUP-2013-019).
Diabetic patients with corneal epithelial defect after vitreoretinal surgery ranging in age from 40 to 75 years old were recruited. Corneal epithelial defect was only induced in patients when there was intraoperative corneal epithelial edema resulting in corneal cloudiness and reduced view for surgery. Epithelial defects were induced using Tookes knife, which debrided the superficial cornea only until the depth of the Bowman membrane. Epithelial defects were near total in most cases. Written informed consent was obtained from all patients before recruitment into the study.
Patients with underlying ocular surface disease such as severe dry eye, limbal stem cell deficiency, or previous ocular trauma especially with history of chemical injury were excluded from the study. Patients on long-term antiglaucoma eye drops, long-term contact lens users, or allergic eye disease necessitating regular topical medications were also excluded. Postoperative patients who developed ocular infection with additional medications were also excluded from the study.
Subsequently, patients were randomized to 4 treatment groups: DNS [topical 0.9% normal saline 4 times per day (QID)], DTI 0.5 (topical insulin 0.5 units QID), DTI 1 (topical insulin 1 units QID), or DTI 2 (topical insulin 2 units QID). Nursing staff or vitreoretinal team members that were not involved in the study randomly selected a sealed envelope containing treatment information for each patient. The same person was assigned to prepare the topical insulin according to a written preparation protocol. Researchers who were involved the data analysis (T.S.F. and M.L.C.B.) and patients were blinded to the treatment. All eye drop bottles were of similar appearance and were labeled with only the patient name and dosing without the medication name.
All patients received a similar regime of topical steroid (dexamethasone 0.1%) and topical antibiotic (ciprofloxacin 0.3%) every 2 hours to the operated eye, which was tapered after 1 week. Topical normal saline or topical insulin eye drops were discontinued once the corneal epithelial defect had healed and patients were discharged. They were reviewed 1 week and 1 month later in the clinic.
The insulin used in this study was Actrapid HM 100 U/mL from Novo Nordisk, Denmark. The insulin eye drops were prepared and diluted with 0.9% normal saline. One bottle of Actrapid HM consists of 1000 U (100 U/mL). A total of 1.25 mL of Actrapid HM (125 U) was added to 3.75 mL of normal saline (total 5 mL) into the commercial applicator bottle. The final solution became 125 U of Actrapid in 5 mL solution (this is equivalent to 25 U/mL of insulin solution). It was assumed that 1 standard drop would result in 20 µL of fluid retained by the eye corresponding to the average volume of the inferior conjunctival sac. Hence, 1 mL would contain 25 U of insulin. One drop of 25 U/mL insulin eye drop was equivalent to 0.5 U per drop (topical insulin 0.5 units). With similar assumption and calculations, 1 unit of topical insulin was prepared by adding 2.5 mL of Actrapid HM (250 U) to 2.5 mL of normal saline (total 5 mL), whereas 2 units of topical insulin consisted of 5 mL of Actrapid HM (500 U) without normal saline. Compounds were given as a single drop from the commercial applicator bottle to the central cornea of the study eye, with the lower eyelid pulled inferiorly during instillation to facilitate application into the eye.
Fluorescein was used to stain the corneal epithelial defect and serial corneal photographs were taken with a digital camera from a mobile phone (iPhone5; Apple, United States) without the use of an adapter 2 hours after operation (t = 0 h) and at every 12-hour interval subsequently (t = 12 h, t = 24 h … t = 72 h) until 72 hours. The iPhone 5 camera features photographs of 5 megapixels with auto focus, high dynamic range (HDR), and 1.4 µm pixel size.
13 Corneal photographs were taken with the mobile phone held 8 cm in front of the eye without magnification while patients rested their chins on the slit lamp. Cobalt blue filtered light from the slit lamp was used.
All patients were admitted to the ophthalmology ward to facilitate corneal photography until there was healing of the epithelial defect. Topical insulin or normal saline was discontinued and patients were discharged once the corneal epithelial defect healed completely. If the corneal epithelial defect did not heal after 72 hours, patients were discharged on topical insulin or placebo and another corneal photograph was taken on the sixth postoperative day (t = 144 h). If corneal epithelial defect persisted for more than 8 days without sign of improvement, rescue treatment with intensive preservative-free artificial tears or bandage contact lens was used. All topical medications were commenced immediately after the first anterior segment photograph was taken.
Two researchers (T.S.F. and M.L.C.B.) who were blinded to the patient groups manually outlined the epithelial defect on fluorescein stained anterior segment photographs using the software program ImageJ, which then measured the surface area of the defect in mm 2 (Fig. 1) . ImageJ is a public domain software developed by Wayne Rasband formerly of the US National Institute of Health (NIH) for research purposes.
14 It enables the user to set a scale at a fixed distance from the selected picture and convert the pixel of the selected distance to the unit that was desired. Subsequently, the selected area could be outlined and calculated in the pre-set unit. For example, a vertical line is carefully marked from the superior limbus at the cornea to the opposite inferior limbus at the maximum corneal diameter. This then allows conversion of the pixels of the selected distance to millimeters (vertical cornea diameter = 11 mm). The selected area (epithelial defect) is then outlined to calculate the surface area in mm 2 . The area of the cornea in each photograph is also calculated. This allows the percentage epithelial defect to be calculated.
Sample size was obtained by using an online calculator from Snedecor and Cochran (1989) . Based on the study by Zagon, 10 the dependence variable was healing rate (mm²/h), the control group had a mean rate of re-epithelialization of 0.53 ± 0.02 mm²/h in comparison with the diabetic group (0.44 ± 0.03 mm²/h). Comparison of the rates of wound healing between the control and the treatment groups differed at the P < 0.05 level.
The calculated sample size for each group was as follows: sample size = 1+ 2C (δ / μ)²; C = constant (if power of study 90%, significance level 0.01, then C = 14.88); δ = standard deviation; μ = the difference to be detected. In this study, the sample size of each group was as follows: sample size = 1 + 2C (δ / μ)²; = 1 + 2 x 14.88 (0.03 / 0.50-0.44)²; = 8.44.
In the subgroup analysis, the online calculator of sample size and power from Vanderbilt University was used. In the previous study by Zagon, 10 the response within each subject group was normally distributed with a standard deviation of 0.02. If the true difference in the experimental and control means is 0.03, 8 experimental subjects and 8 control subjects were needed to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) 0.8. Therefore, the sample size required for each group was 8.
The mean rate of corneal epithelial defect was calculated using the first image (maximum defect) at baseline until the defect was seen to be smallest before complete closure (minimum defect). Mean size of epithelial defect (mm 2 ) and the healing rate (mm 2 per hour) over each interval were also calculated. The reason for choosing maximum defect to minimum defect was to make the calculation of the mean rate of epithelial healing more accurate, as the photo taking sessions were 12 hours apart and the exact time of full epithelial healing was not known. All data was analyzed with SPSS version 23.
RESuLTS
Thirty-three eyes from 33 patients were recruited. One patient developed a lung infection and acute kidney failure in the ward after operation and was excluded from the study. This left a total of 32 eyes that were recruited, with 8 in each group. The demographic data of the patients is tabulated in Table 1 . Patient age ranged from 45 to 71 years. Patients in the DTI 2 group were younger compared with other groups but the mean age difference among all groups was not statistically significant (P = 0.286). The majority of patients in each group were male except in the DNS group. The ethnic distribution in each group was similar to the ethnic distribution in Malaysia, where Malays are the majority and reflect the catchment area. Mean hemoglobin (Hb) A1c among all groups was not statistically significant (P = 0.882). Indications for vitrectomy surgery and type of surgery performed are tabulated in Table 2 and Table 3 .
Advanced diabetic eye disease was the most common indication for vitrectomy for diabetic patients in this study. Types of surgery were individualized based on the patient's ocular condition and no specific pattern or trend was noted.
Thirty-one (96.9%) patients' epithelial defects healed within 144 hours after operation. One patient healed on day 8 postoperatively without need for additional topical medications and without complications (DNS group). Figure 2 shows the duration to complete closure of the epithelial defect. The longest duration to healing was seen in the DNS patients.
From Figure 2 , all patients (100%, n = 8) from the DTI 0.5, FIguRE 2. Duration of healed corneal epithelial defect. DTI 1, and DTI 2 groups healed within 144 hours after operation. Patients in the DTI 0.5 group achieved the highest percentage of full corneal epithelial healing within 72 hours after operation (n = 8, 100%) compared with other treatment arms. Patients in the DNS group took the longest time to heal, with 62.5% (n = 5) of patients achieving complete healing within 72 hours after operation. Similar results were seen in the DTI 2 group. Seventy-five percent (n = 6) of eyes in the DTI 1 group healed within 72 hours. None of the patients reported any adverse reactions toward the topical treatment given during treatment and follow-up.
One-way analysis of variance (ANOVA) test found no statistical difference in the size of corneal epithelial defect between the treatment groups and control at baseline before commencement of topical medications (size of corneal epithelial defect at t = 0; P = 0.935; Table 4 ). Table 4 also shows the epithelial healing rate from baseline to closure. Table 5 and Figure 3 demonstrate the epithelial healing rate at different intervals. The DTI 0.5 group achieved the highest rate from baseline to closure compared with other groups, with the peak rate at 36 hours. On the other hand, the DTI 2 group was slowest from baseline to closure, with the peak rate at 36 hours. The DNS group showed a peak rate at 48 hours and DTI 1 at 24 hours.
The mean rate of corneal epithelial defect improvement in terms of percentage per hour from the maximum baseline defect to minimum closure before total healing was calculated. MannWhitney U tests were used to compare each group (Table 6) .
Eyes in the DTI 0.5 group healed significantly faster than diabetic patients who received topical normal saline (DTI 0.5 vs DNS group, P = 0.036) from baseline to closure and also at 1.34 ± 0.44 *P = 0.935 by ANOVA test to study significant differences of epithelial defect at baseline (P < 0.05 was considered significant). 12-hour and 60-hour intervals. The DTI 1 and DTI 2 groups did not show any statistical difference compared with DNS (DTI 1 vs DNS, P = 0.294; DTI 2 vs DNS, P = 0.834). The DTI 1 group did show a significantly faster rate at 24 hours. However, this seemed to slow down at other intervals. On the other hand, the DTI 2 group did not show any significant difference from baseline to closure compared with DNS. Interobserver reliability between 2 observers (T.S.F. and M.L.C.B.) on the corneal wound measurement for each time interval was tested by using intraclass correlation coefficient (ICC).
The ICC values showed a good consistency and reliability between the 2 observers. It ranged from 0.82 to 0.988, with a 95% confidence interval.
DISCuSSION
Diabetes alters the morphology of the corneal epithelium and its basement membrane. This leads to epithelial fragility and poor epithelial adherence once epithelial defect has occurred.
3,4 Apart from morphological changes, loss of corneal nerve plexus and decreased corneal sensation also play a role in the development of diabetic keratopathy. This is due to loss of nerve-derived trophic factor that plays an important role in epithelial proliferation and migration.
15 Interestingly, it is this decreased sensation that prevents diabetic keratopathy from being acutely painful unlike corneal abrasion in normal individuals. However, this also means such patients present late due to lack of symptoms. Nakamura et al 16 have shown that insulin-like growth factor and substance P (both are neuropeptides present in sensory nerves) accelerate corneal epithelial wound healing in diabetic animals.
This study showed that the majority of patients achieved their peak rate of epithelial healing between 24 and 48 hours. This may represent the migration phase during the process of corneal epithelial healing, which is known to occur around 24-48 hours after corneal epithelial injury.
17,18
The most effective topical insulin concentration was 0.5 units in this study. It was more effective at 12 hours and 60 hours compared with diabetic placebo. It differed from the results demonstrated in the study by Bastion et al 7 where 1 unit of topical insulin was used. However, the sample size of that retrospective study was small and only consisted of 5 eyes on topical insulin. Of note, DTI 1 eyes did have a significantly faster rate of healing at 24 hours compared with DNS (Table 5 ). However, this rate seemed to slow down during the subsequent time intervals. A number of postulations including toxicity from insulin due to its higher concentration compared with 0.5 units and its viscosity may also slow down the migration of epithelial cells during the healing process. This could also explain the lack of any significant benefit in using 2 units of insulin at all study intervals.
Undiluted Actrapid HM from Novo Nordisk consists of 1000 IU recombinant insulin and trace excipients such as zinc chloride, glycerol, metacresol, sodium hydroxide, hydrochloric acid, and water for injection.
19 None of these trace excipients have been reported to be beneficial for corneal epithelial healing even though zinc was postulated to have a role in wound healing of the skin. Zinc acts as a cofactor in numerous transcription factors and enzyme systems, which include zinc-dependent matrix metalloproteinases that are important during autodebridement and keratinocyte migration during wound repair. 20, 21 Sodium hydroxide and hydrochloric acid act as pH adjustment agents in Actrapid HM but pH changes may occur once it is instilled into the human eye. Even though Bartlett et al 11 showed no ocular toxicity of topical insulin in their study, pH changes were not studied. Patients who received 1 and 2 units of topical insulin did not report symptoms of pain upon instillation. Two units of topical insulin used in this study was noted to be more viscous and could have altered the ocular pH as well. However, as pH effects on wound healing were not studied here, these could be areas for future study.
The ocular morbidity of slow healing epithelial defects is well illustrated by the DNS eye, which healed only after 144 hours. On review of the patient, it was noted that she underwent vitrectomy for advanced diabetic eye disease and had been a diabetic for 5 years with HbA1c of 7.6% before the operation. This case reflects the need for ocular lubrication and treatment for slow healing epithelial defect in diabetic patients.
This study has allowed direct comparison among topical insulin of 3 concentrations in diabetic patients for the treatment of epithelial defect. Topical insulin of 0.5 units QID can therefore be considered in the treatment of diabetic patients undergoing vitrectomy who develop postoperative epithelial defect or who have their epithelium debrided. Other applications for 0.5 units of topical insulin include nonsurgical induced epithelial defect in diabetic patients such as after trauma. Further clinical trials are required in this group of patients.
The advantages of topical insulin are that it is readily available and cheaper in price as compared with conventional preservative-free artificial tears. Only a few milliliters of insulin are required for the preparation of 0.5 units of topical insulin sufficient for 1 week.
The main limitations of this study include its small sample size. This is a reflection of the limited number of patients who require corneal debridement intraoperatively in our center. Ideally, a longer study period would be helpful for the recruitment of more patients and longer follow-up of patients to detect late onset of complications. Intraoperative debridement should never be deliberate.
The other areas for improvement for future study include closer follow-up and hourly serial photography with better image resolution. An anterior segment camera with better resolution was not used in this study because access to it during the weekend when most of our postvitrectomy patients were hospitalized was not possible. With limited resources, a mobile phone camera with good resolution was used in the study to ensure consistent quality of the photographs. Even though Image-J is a useful tool in measuring surface area from the corneal photo, alternative methods of measuring may be explored in the future. Standard-sized epithelial defects can be marked using corneal trephine blades (Beaver trephine blade) with standard size before debridement, which is another option in view of the rate of healing being faster when the defect is smaller. However, depending on eyeball size, a standard-sized defect might not be ideal for completion of vitrectomy in real life due to blurred image when viewed through the corneal periphery.
Topical insulin of 0.5 units QID is the most effective concentration in healing of postvitrectomy corneal epithelial defect in diabetic patients with iatrogenic epithelial defect after vitrectomy. Topical insulin of 0.5 units, 1 unit, and 2 units were safe for human usage without any adverse effect.
